öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ººú°®ÈÙ
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º532

ËùÊôԺУ£ºÄþ²¨´óѧ
ËùÊôԺϵ£ºÒ½Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ¿Æѧ
Ñо¿ÁìÓò£º ¸ÐȾ²¡¼°¸Î²¡µÄ»ù´¡ÓëÁÙ´²Ñо¿
Ñо¿ÁìÓò£º ¸ÐȾ²¡¼°¸Î²¡µÄ»ù´¡ÓëÁÙ´²Ñо¿ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºhuairong6666@126.com
ͨѶµØÖ·£ºÄþ²¨Êк£ÊïÇøÎ÷±±½Ö41ºÅ


¸öÈ˼òÊö :
ºú°®ÈÙÖ÷ÈÎҽʦ£¬ÄУ¬1975Äê³öÉú£¬Ë¶Ê¿Ñо¿Éú¡£ÔøÔÚÕã½­´óѧ¸½ÊôµÚÒ»Ò½Ôº¸ÐȾ¿Æ½øÐÞ°ëÄꡣרעÓÚ¸ÐȾ²¡¼°¸ÎÔಡµÄÁÙ´²Óë»ù´¡Ñо¿¡£ÀúÈÎÁÙ´²¿ÆÊÒ¸±Ö÷ÈΡ¢Ö÷ÈΡ¢¿ÆÑпƿƳ¤£¬ÏÖΪÄþ²¨Êиβ¡Ñо¿Ëù³£Îñ¸±Ëù³¤¡£ÓнÏÇ¿µÄÁÙ´²Óë¿ÆÑÐ×é֯ʵʩÄÜÁ¦¡£Í¨¹ý¹ú¼ÒÐÄÀí×Éѯʦ¶þ¼¶öλÔÓéÀֵǼÈë¿ÚÏÂÔؼ°Ê¡Ò½Ñ§ÊµÑ鶯Îï×ʸñöλÔÓéÀֵǼÈë¿ÚÏÂÔØ¡£

Äþ²¨´óѧ˶ʿÉúµ¼Ê¦£¬ÍîÄÏҽѧԺ˶ʿÉúµ¼Ê¦¡£Äþ²¨ÊпƼ¼¾Ö¡°ÉúÎïÖÎÁÆÓë¸Î²¡·ÀÖδ´ÐÂÍŶӡ±¼¼Êõ¹Ç¸É£¬Õã½­Ê¡ÇøÓòר²¡ÖÐÐĽ¨Éèר¿Æ£¨¸ÐȾ¿Æ£©ºó±¸´øÍ·ÈË£¬Õã½­Ê¡Ê¡Êй²½¨Ò½Ñ§Öصãѧ¿Æ£¨´«È¾²¡Ñ§£©ºó±¸´øÍ·ÈË£¬Äþ²¨ÊÐÁÙ´²Öصãר¿Æ¡ª¡ª¸Î²¡¿Æ£¨¸ÎÓ²»¯£¬¸ÎÖ×Áö£©ºó±¸´øÍ·ÈË£¬Õ㽭ҽʦЭ»á¸ÐȾ²¡Öصãѧ¿Æºó±¸´øÍ·ÈË£¬Õã½­Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò£¬Õã½­Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò£¬¸£ÖÝÊкÍÏÃÃÅÊпƼ¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò¡£

È«¹ú¸Îµ¨²¡×Éѯר¼Ò£¬È«¹úÒÉÄѼ°ÖØÖ¢¸Î²¡¹¥¹ØЭ×÷×éίԱ£¬ÖйúÖÐÎ÷Ò½½áºÏѧ»áÄÚ·ÖÃÚöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬ÖлªÒ½Ñ§»áÈÈ´ø²¡Óë¼ÄÉú³æ·Ö»áÇàÄêίԱ»áίԱ£¬Õ㽭ʡҽѧ»áÈÈ´ø²¡Óë¼ÄÉú³æ·Ö»áÇàÄêίԱ»á¸±Ö÷ÈÎίԱ£¬Õã½­Ê¡ÊýÀíҽѧ»á¸Î²¡Ñ§·Ö»á³£Î¯£¬Õ㽭ʡҽʦЭ»á¸ÐȾ¿Æҽʦ·Ö»áίԱ£¬Õã½­Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¸ÐȾ²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬Õã½­Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¸Î²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬Äþ²¨ÊÐÖÐÎ÷Ò½½áºÏѧ»á¸Î²¡Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈÎίԱ£¬Äþ²¨ÊÐҽѧ»á¸Î²¡Ñ§·Ö»áίԱ£¬Äþ²¨ÊÐҽѧ»á¸ÐȾ²¡Ñ§·Ö»áίԱ¡¢ÃØÊé¡£

Õã½­Ê¡¡°151¡±È˲ţ¨2012Äê¡¢µÚÈý²ã´Î£©£¬Äþ²¨ÊС°4321¡±È˲ţ¨2012Äê¡¢µÚ¶þ²ã´Î£©£¬Äþ²¨ÊÐÓÅÐãÖÐÇàÄêÎÀÉú¼¼ÊõÈ˲ţ¨2012Ä꣩£¬Äþ²¨ÊÐÁì¾üºÍ°Î¼âÈ˲ÅÅàÑø¶ÔÏó£¨2015Äê¡¢µÚ¶þ²ã´Î£©£¬Õã½­Ê¡Ò½Ò©ÎÀÉú¸ß¼¶È˲ţ¨Ò½Ì³ÐÂÐ㣩£¨2017Ä꣩¡£

¡¶ÏÖ´úÖÐÎ÷Ò½½áºÏÔÓÖ¾¡·¼°¡¶ÖйúÏÖ´úÒ½Éú¡·±àί£¬Á¬Ðø3´Î»ñµÃ¡¶ÁÙ´²¸Îµ¨²¡ÔÓÖ¾¡·ÓÅÐãÉó¸åר¼Ò£¬¡¶Öйú²¡¶¾²¡ÔÓÖ¾¡·¡¢¡¶Ò½Ñ§Ñо¿ÔÓÖ¾¡·¡¢¡¶ÏÖ´úʵÓÃҽѧ¡·Éó¸åר¼Ò£¬¡¶Frontiers of Medicine¡·¡¢¡¶World Journal of Gastroenterology¡·¡¢¡¶Journal of Clinical & Experimental Pathology¡·¡¢¡¶Oncotarget¡·µÈÆÚ¿¯Í¬ÐÐÆÀÒéר¼Ò¡£

¡¡¡¡½ü5ÄêÖ÷³Ö»òÖ÷Òª²ÎÓë¹ú¼Ò×ÔÈ»»ù½ðÇàÄê»ù½ð£¨µÚ2룩¡¢Îâ½×ƽҽѧ»ù½ð»á¿ÎÌ⣨µÚ1룩¡¢Öйú¸ÎÑ×·ÀÖλù½ð»á¿ÎÌ⣨2Ïî¡¢µÚ1룩¡¢Õã½­Ê¡×ÔÈ»»ù½ð£¨µÚ3룩¡¢Õã½­Ê¡Ò½Ò©ÎÀÉúÊ¡²¿ÅàÓý¼Æ»®£¨µÚ1룩¡¢Ê¡Êй²½¨¼Æ»®£¨µÚ1룩¡¢Ò»°ã¼Æ»®£¨µÚ1룩¡¢Äþ²¨ÊÐÉç·¢ÖØ´óÏîÄ¿µÈ¿ÆÑпÎÌâ12Ï²ÎÓëÈ«Çò¼°È«¹úÁÙ´²ÊÔÑé6Ïî¡£

¡¡¡¡»ñµÃ2011Äê¶ÈÖлªÖÐҽҩѧ»á¿Æѧ¼¼Êõ¶þµÈ½±£¨²ÎÓëÕߣ©£¬2014Äê¶ÈÕã½­Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¶þµÈ½±£¨µÚһ룩£¬2016Äê¶ÈÄþ²¨ÊпƼ¼½ø²½½±ÈýµÈ½±£¨µÚһ룩¡£Äþ²¨ÊÐ×ÔÈ»¿ÆѧÓÅÐãÂÛÎĽ±£¨ÓÅÐã½±2´Î£©£¬¹ú¼Ê¼¶È«¹ú»áÒéÂÛÎĽ±12´Î¡£

·¢±íÂÛÎÄ120Óàƪ£¬ÆäÖÐÒÔµÚÒ»×÷Õß/ͨÐÅ×÷Õß·¢±íSCIÂÛÎÄ9ƪ¡£Ö÷±àöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®1±¾£¬¸±Ö÷±à¡¢¸±Ö÷ÒëöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®3±¾£¬²Î±à¡¢²ÎÒëöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®5±¾£»ÔÚGenBank×¢²áºËÜÕËáÐòÁÐ1Ìõ£¨ÐòÁкÅ£ºHQ828086.1£©¡£


¿ÆÑй¤×÷ :
·¢±íÂÛÎÄ120Óàƪ£¬ÆäÖÐÒÔµÚÒ»×÷Õß/ͨÐÅ×÷Õß·¢±íSCIÂÛÎÄ9ƪ¡£Ö÷±àöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®1±¾£¬¸±Ö÷±à¡¢¸±Ö÷ÒëöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®3±¾£¬²Î±à¡¢²ÎÒëöλÔÓéÀֵǼÈë¿ÚÏÂÔØÊé¼®5±¾¡£

SCIÆÚ¿¯ÂÛÎÄ£¨²¿·Ö£©

1£© Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure£¬Hepatol Res£¬2017£¬Í¨ÐÅ×÷Õß

2£©Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis£¬Evid Based Complement Alternat Med£¬2017£¬ÅÅÃû3

3£©Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation£¬Biol Pharm Bull£¬2017£¬ÅÅÃû3

4£©Hepatomacell-derivedleptindownregulatestheimmunosuppressivefunctionofregulatoryT-cellstoenhancetheanti-tumoractivityofCD8(+)T-cells£¬Immunol Cell Biol£¬2016£¬ÅÅÃû5

5£©Quantification and pharmacokinetic study of sorafenib in rat plasma using UPLC-MS/MS£¬Latin American Journal of Pharmacy£¬2016£¬Í¨ÐÅ×÷Õß

6£©Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS£¬J Chromatogr B Analyt Technol Biomed Life Sci£¬2015£¬Í¨ÐÅ×÷Õß

7£©DNA repair gene XRCC3 T241M polymorphism and susceptibility to hepatocellular carcinoma in a Chinese population: a meta-analysis£¬Genetics and Molecular Research£¬2015£¬Í¨ÐÅ×÷Õß

8£©Diagnostic value of serum Golgi protein 73 for HBV-related primary hepatic carcinoma£¬Int J Clin Exp Pathol£¬2015£¬Í¨ÐÅ×÷Õß

9£©Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates£¬World Journal of Gastroenterol£¬2014£¬Í¨ÐÅ×÷Õß

ºËÐÄÆÚ¿¯ÂÛÎÄ£¨²¿·Ö£©

1£©Äþ²¨µØÇø³ÉÈ˼°Ð¡¶ùÖØÖ¢¼×ÐÍH1N1Á÷¸ÐÁ÷Ðв¡Ñ§¼°ÁÙ´²ÕïÖζԱȷÖÎö£¬ÖлªÖÐҽҩѧ¿¯£¬2012£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯

2£©Õã½­Ê¡¶«²¿µØÇøÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕß°¢µÂ¸£Î¤õ¥Ïà¹Øλµã²¡¶¾±äÒìµÄÁÙ´²ÌØÕ÷·ÖÎö£¬ÖлªÒ½Ñ§ÔÓÖ¾£¬2012£¬µÚÒ»×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

3£©ºÎÊ×ÎÚ¼°ÆäÖƼÁÖÂÒ©ÎïÐÔ¸ÎËðÉË52ÀýÁÙ´²·ÖÎö£¬ÖлªÖÐҽҩѧ¿¯£¬2013£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯

4£©ÇáÖ¢ºÍÖØÖ¢¼×ÐÍ H1N1Á÷¸Ð»¼ÕßÃâÒßѧÌØÕ÷±È½Ï·ÖÎö£¬2013£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

5£©·Î½áºË»¼Õ߼̷¢ÏºôÎüµÀ¸ÐȾµÄ²¡Ô­¾ú·Ö²¼¼°ÄÍÒ©ÐÔ·ÖÎö£¬ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2013£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-E

6£©ÊÖ×ã¿Ú²¡ÖØÖ¢»¯µÄΣÏÕÒòËØ¡¢²¡Àí¸Ä±ä¼°ÁÙ´²¸ÉÔ¤£¬ÖлªÊµÑéºÍÁÙ´²²¡¶¾Ñ§ÔÓÖ¾£¬2013£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

7£©ÁÙ´²²¡Àíʬ¼ìÓë·¨Ò½²¡Àíʬ¼ìµÄ¶Ô±È·ÖÎö£¬ÖлªÈ«¿Æҽѧ£¬2013£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

8£©ÊäÈëÐÔ¶ñÐÔű28ÀýÁ÷Ðв¡Ñ§¼°ÁÙ´²ÌØÕ÷·ÖÎö£¬ÖлªÈ«¿Æҽѧ£¬2014£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

9£©Äþ²¨µØÇø±ûÐ͸ÎÑײ¡¶¾»ùÒò·ÖÐͼ°¸ÐȾ״¿ö·ÖÎö£¬ÖлªÁÙ´²¸ÐȾ²¡ÔÓÖ¾£¬2014£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

10£©ÍÁÜòÜß×é·½ÔÚÒÒÐ͸ÎÑײ¡¶¾Âý¼Ó¼±ÐÔ¸ÎË¥½ßÖеÄÓ¦Óü°ÁÆЧ·ÖÎö£¬ÖлªÖÐÒ½Ò©ÔÓÖ¾£¬2015£¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-E

11£©ºËÜÕ(Ëá)ÀàÒ©ÎïÓ¦ÓÃÓëHBVÏà¹ØÂý¼Ó¼±ÐÔ¸ÎË¥½ß½üÆÚÔ¤ºó·ÖÎö£¬Öлª¸ÎÔಡÔÓÖ¾£¬2015£¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

12£©Õã½­Ê¡¶«²¿µØÇø±ûÐ͸ÎÑײ¡¶¾»ùÒò·ÖÐ͵ÄÑо¿£¬ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2015£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-E

13£©ÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕß1397Àý¸Î×éÖ¯²¡ÀíºÍÁÙ´²ÌØÕ÷·ÖÎö£¬ÖлªÁÙ´²¸ÐȾ²¡ÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

14£©ÂýÐÔ±ûÐ͸ÎÑ×»¼Õß±ê×¼»¯ÖÎÁÆÓ¦´ðµÄÏà¹ØÒòËØ·ÖÎö£¬ÖлªÈ«¿Æҽѧ£¬2016£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

15£©¸ÎÓ²»¯¼±ÐÔÉöËðÉ˼°¸ÎÉö×ÛºÏÕ÷µÄÕïÖη¾¶£¬ÖлªÎ£Öز¡¼±¾Èҽѧ£¬2016£¬µÚÒ»×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

16£©CTÒýµ¼Ï¾­Æ¤´©´Ì»î¼ì¼¼ÊõÔÚ¼¹Öù¸ÐȾ²¡±äÕï¶ÏÖеÄÓ¦ÓÃÑо¿£¬ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-E

17£©ÒÒÐ͸ÎÑ×Ïà¹ØÂý¼Ó¼±ÐÔ¸ÎË¥½ßÔçÆÚ¼°Ô¶ÆÚÔ¤ºóµÄÓ°ÏìÒòËرȽϷÖÎö£¬ÖлªÊµÑéºÍÁÙ´²²¡¶¾Ñ§ÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

18£©·Ç»î¶¯ÐÔHBsAgЯ´øÕß110Àý¸Î×éÖ¯µÄ²¡ÀíѧÌØÕ÷£¬ÖлªÈ«¿ÆҽʦÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

19£©ºËÜÕ£¨ËᣩÀàËÆÎïÓë¸ÉÈÅËØÁªºÏÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ׵ĽøÕ¹£¬Öлª´«È¾²¡ÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

20£©ÑªÇå±û°±Ëáת°±Ã¸Õý³£ÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾ»¼Õ߸Î×éÖ¯²¡ÀíѧÌØÕ÷·ÖÎö£¬ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2016£¬µÚÒ»×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-E

21£©ÎÞ´´Õï¶ÏÊýѧģÐͶÔÒÒÐ͸ÎÑײ¡¶¾Ïà¹Ø¸ÎÏËά»¯µÄÕï¶Ï¼ÛÖµ£¬Öлª´«È¾²¡ÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

22£©±û°±Ëá°±»ùתÒÆøÕý³£ÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕߵĸÎ×éÖ¯²¡ÀíѧÌØÕ÷£¬Öлª¸ÎÔಡÔÓÖ¾£¬2016£¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

23£©±û°±Ëáת°±Ã¸Ð¡ÓÚ2±¶Õý³£ÖµÉÏÏÞÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕß1148ÀýµÄ¸ÎÔಡÀíѧ¸Ä±ä¼°Ó°ÏìÒòËØ£¬Öлª´«È¾²¡ÔÓÖ¾£¬2016£¬Í¨ÐÅ×÷Õߣ¬ÖÐÎĺËÐÄÆÚ¿¯¡¢CSCD-C

24£©Õï¶ÏÄ£ÐͶÔALTÕý³£ÖµÉÏÏÞ2±¶ÒÔÏÂÂýÐÔHBV¸ÐȾÕßÖÎÁÆÖ¸Õ÷µÄÅжϼÛÖµ£¬ÖлªÈ«¿Æҽѧ£¬2017£¬Í¨ÐÅ×÷Õߣ¬¿Æ¼¼ºËÐÄÆÚ¿¯

»áÒéÂÛÎÄ

1£©Antiviral therapy with nucleoside and nucleotideanalogs improves the long-term prognosis in patients with chronic hepatitis B-associated liver failure£¬EASL - THE INTERNATIONAL LIVER CONGRESS? 2016£¬ÅÅÃû1£¨´ó»á·¢ÑÔ£©

2£© Analysis of HBV gene mutations related to NAs in chronic HBV infection£¬the 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL2016)£¬ÅÅÃû1£¨±Ú±¨Õ¹Ê¾Ö÷ϯ£©

3£© 1 397ÀýÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕ߸Î×éÖ¯µÄ²¡ÀíѧÌØÕ÷·ÖÎö£¬ÖлªÒ½Ñ§»áµÚÊ®ËÄ´ÎÈ«¹ú¸ÐȾ²¡Ñ§Êõ»áÒ飬2016£¬ÅÅÃû1£¨´ó»á·¢ÑÔ£©

Öø×÷

1£©¸Î²¡Ö¸ÄÏÓëÁÙ´²Êµ¼ù£¬Ç廪´óѧ³ö°æÉ磬2017£¬¸±Ö÷±à

2£©»¼Õß×Éѯ³£¼ûÎÊÌâÓë½â´ð´ÔÊ飺¸ÐȾÐÔ¼²²¡Óë¸Î²¡£¬»¯Ñ§¹¤Òµ³ö°æÉ磬2014£¬Ö÷±à

3£©Sherlock¸Îµ¨²¡Ñ§£¨µÚ12°æ£©£¬ÈËÃñÎÀÉú³ö°æÉ磬2014£¬²ÎÒë

4£©¸ÎÔಡѧ£¨ÁÙ´²²¡Àý½âÎö£©£¬ÈËÃñÎÀÉú³ö°æÉ磬2013£¬¸±Ö÷Òë

5£©´«È¾²¡Ñ§£¬¾üÊÂҽѧ¿Æѧ³ö°æÉ磬2012£¬±àί

6£©Å·ÃÀ¸Î²¡ÕïÁÆʵÓÃÊֲᣬ»¯Ñ§¹¤Òµ³ö°æÉ磬2012£¬¸±Ö÷±à

7£©²¡¶¾ÐÔ¸ÎÑסªÀ§»óÓëÌôÕ½£¬ÈËÃñÎÀÉú³ö°æÉ磬2011£¬²ÎÒë

8£©¼ìÑéÓëÁÙ´²µÄ¹µÍ¨¡ª°¸Àý·ÖÎö200Àý£¬ÈËÃñÎÀÉú³ö°æÉ磬2011£¬±àί

9£©ÄÚ¿ÆÒÉÄÑÖØÖ¢²¡ÀýÌÖÂÛ--¸ÐȾÓë¸Î²¡·Ö²á£¬ÈËÃñÎÀÉú³ö°æÉ磬2010£¬±àί
È«¹ú¸Îµ¨²¡×Éѯר¼Ò£¬È«¹úÒÉÄѼ°ÖØÖ¢¸Î²¡¹¥¹ØЭ×÷×éίԱ£¬ÖйúÖÐÎ÷Ò½½áºÏѧ»áÄÚ·ÖÃÚöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬ÖлªÒ½Ñ§»áÈÈ´ø²¡Óë¼ÄÉú³æ·Ö»áÇàÄêίԱ»áίԱ£¬Õ㽭ʡҽѧ»áÈÈ´ø²¡Óë¼ÄÉú³æ·Ö»áÇàÄêίԱ»á¸±Ö÷ÈÎίԱ£¬Õã½­Ê¡ÊýÀíҽѧ»á¸Î²¡Ñ§·Ö»á³£Î¯£¬Õ㽭ʡҽʦЭ»á¸ÐȾ¿Æҽʦ·Ö»áίԱ£¬Õã½­Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¸ÐȾ²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬Õã½­Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¸Î²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬Äþ²¨ÊÐÖÐÎ÷Ò½½áºÏѧ»á¸Î²¡Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈÎίԱ£¬Äþ²¨ÊÐҽѧ»á¸Î²¡Ñ§·Ö»áίԱ£¬Äþ²¨ÊÐҽѧ»á¸ÐȾ²¡Ñ§·Ö»áίԱ¡¢ÃØÊé¡£

Õã½­Ê¡¿Æ¼¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò£¬Õã½­Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò£¬¸£ÖÝÊкÍÏÃÃÅÊпƼ¼¼Æ»®ÏîÄ¿ÆÀÉóר¼Ò¡£

¡¶ÏÖ´úÖÐÎ÷Ò½½áºÏÔÓÖ¾¡·¼°¡¶ÖйúÏÖ´úÒ½Éú¡·±àί£¬Á¬Ðø3´Î»ñµÃ¡¶ÁÙ´²¸Îµ¨²¡ÔÓÖ¾¡·ÓÅÐãÉó¸åר¼Ò£¬¡¶Öйú²¡¶¾²¡ÔÓÖ¾¡·¡¢¡¶Ò½Ñ§Ñо¿ÔÓÖ¾¡·¡¢¡¶ÏÖ´úʵÓÃҽѧ¡·Éó¸åר¼Ò£¬¡¶Frontiers of Medicine¡·¡¢¡¶World Journal of Gastroenterology¡·¡¢¡¶Journal of Clinical & Experimental Pathology¡·¡¢¡¶Oncotarget¡·µÈÆÚ¿¯Í¬ÐÐÆÀÒéר¼Ò¡£
1£©ÒÒÐ͸ÎÑײ¡¶¾RTÇø»ùÒòÄÍÒ©Í»±äµÄÒìÖÊÐÔÑо¿£¬Öйú¸ÎÑ×·ÀÖλù½ð»áÌìÇç¸Î²¡Ñо¿»ù½ð£¬2017£¬10ÍòÔª£¬ÔÚÑУ¬ÅÅÃû1

2£©ÒÒÐ͸ÎÑ×¼²²¡½øչɸ²é¼°ÓÅÑ¡ÓÅ»¯ÕïÖιÜÀíÌåϵÍƹ㣬Äþ²¨ÊÐÒ½Ò©ÎÀÉú¿Æ¼¼¼Æ»®£¬2016£¬6ÍòÔª£¬ÔÚÑУ¬ÅÅÃû1

3£©ÒÒÐ͸ÎÑײ¡¶¾Ïà¹ØÖÕÄ©Æڸβ¡¸öÌ廯ÕïÖεľ«×¼Ò½ÁÆ£¬Äþ²¨ÊÐÉç»á·¢Õ¹ÖØ´óרÏ2016£¬150ÍòÔª£¬ÔÚÑУ¬ÅÅÃû3

4£©»ùÓÚÒȵºËØÐźÅתµ¼»·½ÚµÄÖÐÒ©×é·Ö¡°HJJB¡±¸´·½·ÀÖηǾƾ«ÐÔÖ¬·¾¸Î×÷ÓûúÀíÑо¿£¬¹ú¼Ò×ÔÈ»»ù½ðÇàÄê»ù½ð£¬2016£¬36ÍòÔª£¬ÔÚÑУ¬ÅÅÃû2

5£©ÖÐÒ©×é·Ö¡°HJJB¡±¸´·½¸ÄÉƷǾƾ«ÐÔÖ¬·¾¸Î¸ÎÔàÖ¬·¾´úл»úÖƼ°Ö÷ЧӦ×é·ÖÑо¿£¬Õã½­Ê¡×ÔÈ»»ù½ðÒ»°ãÏîÄ¿£¬2015£¬16ÍòÔª£¬ÔÚÑУ¬ÅÅÃû3

6£©HBV»ùÒò×éÄæת¼ÇøÄÍҩģʽÓëÆäËû¿ª·Å¶ÁÂë¿ò±àÂë»ùÒòÍ»±äµÄÏà¹ØÐÔÑо¿£¬Õã½­Ê¡Ò½Ò©ÎÀÉúÊ¡²¿ÅàÓý¼Æ»®£¬2014£¬20ÍòÔª£¬ÔÚÑУ¬ÅÅÃû1

7£©ÉùÂö³å·øÉäÁ¦³ÉÏñ¶ÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õ߸ÎÏËά»¯µÄÔ¤²â¼ÛÖµÑо¿£¬Öйú¸ÎÑ×·ÀÖλù½ð»áÌìÇç¸Î²¡Ñо¿»ù½ð£¬2014£¬6ÍòÔª£¬ÒÑÑéÊÕ£¬ÅÅÃû3

8£©ÑªÇå¸ß¶û»ùÌåµ°°×73ÔÚÒÒÐ͸ÎÑ×Ïà¹ØÐԸΰ©Õï¶ÏÖеļÛÖµÑо¿£¬Öйú¸ÎÑ×·ÀÖλù½ð»áÌìÇç¸Î²¡Ñо¿»ù½ðÏîÄ¿£¬2012£¬10ÍòÔª£¬ÒÑÑéÊÕ£¬ÅÅÃû2

9£©¡¢pro-ADMÔÚ¸ÎÓ²»¯»¼ÕßÖмø±ðŧ¶¾ÑªÖ¢ÓëÈ«ÉíÑ×Ö¢·´Ó¦×ÛºÏÕ÷¼°ÅжÏÔ¤ºóµÄ¼ÛÖµ£¬Õã½­Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¼Æ»®Ò»°ãÏîÄ¿£¬2015£¬3ÍòÔª£¬ÔÚÑС¢²Î¼Ó£¨µÚ5룩

10£©ÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©ÂýÐÔ¸ÐȾÕß²»Í¬²¡³ÌHBV»ùÒò×éPÇøÔ¤´æÄÍÒ©µÄÁÙ´²Á÷Ðв¡Ñ§Ñо¿£¬Äþ²¨ÊÐ×ÔÈ»»ù½ðÏîÄ¿£¬2013£¬6ÍòÔª£¬ÒÑÑéÊÕ£¬²Î¼Ó£¨µÚ5룩

11£©³¦µÀ²¡¶¾71ÐÍ£¨EV71£©ÖØÖ¢¸ÐȾµÄ·Ö×Ó²¡ÀíѧÑо¿£¬Äþ²¨ÊÐÒ½Ò©ÎÀÉú¿Æ¼¼¼Æ»®ÏîÄ¿£¬2013£¬6ÍòÔª£¬ÒÑÑéÊÕ£¬µÚ1λ

12£©Äþ²¨ÊпƼ¼¾Ö¿Æ¼¼´´ÐÂÍŶÓÏîÄ¿£¨ÉúÎïÖÎÁÆÓë¸Î²¡·ÀÖδ´ÐÂÍŶӣ©£¬2011£¬600ÍòÔª¡¢ÔÚÑУ¬²Î¼Ó£¨µÚ6룩

13£©ÔËÓõ°°×ÖÊ×éѧ¼¼Êõ¹¹½¨ÒÒÐ͸ÎÑ׸ÎÏËά»¯·Ç´´ÉËÐÔÕï¶ÏÄ£ÐÍ£¬Öйú¸ÎÑ×·ÀÖλù½ð»áÌìÇç¸Î²¡Ñо¿»ù½ðÏîÄ¿£¬2010£¬3ÍòÔª£¬ÒѽáÌâ¡¢²Î¼Ó£¨µÚ3룩

14£©¸ÎË¥½ß»¼ÕßÈ˹¤¸ÎÖÎÁÆÇ°ºó¸ÎÔà´¢±¸¹¦Äܱ仯¼°Éú´æ·ÖÎöÑо¿£¬Îâ½×ƽҽѧ»ù½ð»á¸Î¹¦ÄÜÆÀ¼Û·½·¨Ñо¿»ù½ðÏîÄ¿£¬2010£¬10ÍòÔª£¬ÒѽáÌ⣬µÚһλ

15£©Äþ²¨ÊÐÁì¾üºÍ°Î¼âÈ˲ÅÅàÑø¶ÔÏ󣨵ڶþ²ã´Î£©£¬2015Ä꣬ҽѧ

16£©Õã½­Ê¡Ò½Ò©ÎÀÉú¸ß¼¶È˲ÅÅàÑø¶ÔÏó£¨Ò½Ì³ÐÂÐ㣩£¬2013Ä꣬¸ÐȾÐÔ¼²²¡Ñ§

17£©Äþ²¨ÊÐÁì¾üºÍ°Î¼âÈ˲ţ¨µÚ¶þ²ã´Î£©£¬2015Ä꣬ҽѧ

18£©Äþ²¨ÊÐÓÅÐãÖÐÇàÄêÎÀÉú¼¼ÊõÈ˲Å£¬2012Ä꣬´«È¾²¡Ñ§

19£©Õã½­Ê¡151È˲Å£¬2012Ä꣬ҽѧ

20£©Äþ²¨ÊÐ4321È˲Å£¬2011Ä꣬ҽѧ
1£©Äþ²¨µØÇøÒÒÐ͸ÎÑײ¡¶¾±äÒìµÄ·Ö×ÓÁ÷Ðв¡Ñ§Ñо¿£¬Õã½­Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¶þµÈ½±£¬2014£¬ÅÅÃû1

2£©ÖÐÒ©¸´·½ÖƼÁÖÎÁÆÂýÐÔÒҸΡ¢¸ÎÏËά»¯µÄ»ù´¡¼°ÁÙ´²Ñо¿£¬ÖлªÖÐҽҩѧ»á¿Æѧ¼¼¶þµÈ½±£¬2011£¬ÅÅÃû10

3£©ÒÒÐ͸ÎÑײ¡¶¾±äÒìµÄ·Ö×ÓÁ÷Ðв¡Ñ§·ÖÎö£¬xxÊпƼ¼½ø²½½±ÈýµÈ½±£¬2016£¬ÅÅÃû1

4£©Ê״λñµÃÄþ²¨µØÇøÊÖ×ã¿Ú²¡EV71²¡¶¾µÄÈ«»ùÒòÐòÁУºEV 71Äþ²¨·ÖÀëÖêµÄÈ«»ùÒò³¤¶ÈΪ7,414¸ö¼î»ù£¬ÎªC4ÑÇÐÍ£¬ÃüÃûΪNBChina01£¬ÔÚGenBank µÄ×¢²áµÇ¼ÇºÅΪHQ828086.1¡£Í¨¹ýncbi nucleotide blast £¨http://blast.ncbi.nlm.nih.gov/£©ÏµÍ³²¢ÓëGeneBankÖÐEV71ÆäËûµÄÐòÁУ¨EU812515.1£©½øÐбȽÏ£¬Í¬Ô´ÐÔΪ98%¡£